TNF Pharmaceuticals, Ownership
| TNFA Stock | 1.36 0.11 7.48% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
TNF |
TNF Stock Ownership Analysis
About 40.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. TNF Pharmaceuticals, recorded a loss per share of 10.48. The entity last dividend was issued on the 25th of November 2019. The firm had 1:30 split on the 15th of February 2024. To find out more about TNF Pharmaceuticals, contact the company at 856 848 8698 or learn more at https://tnfpharma.com.Besides selling stocks to institutional investors, TNF Pharmaceuticals, also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different TNF Pharmaceuticals,'s stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align TNF Pharmaceuticals,'s strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
TNF Pharmaceuticals, Quarterly Liabilities And Stockholders Equity |
|
About 6.0% of TNF Pharmaceuticals, are currently held by insiders. Unlike TNF Pharmaceuticals,'s institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against TNF Pharmaceuticals,'s private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of TNF Pharmaceuticals,'s insider trades
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether TNF Pharmaceuticals, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of TNF Pharmaceuticals,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tnf Pharmaceuticals, Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tnf Pharmaceuticals, Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TNF Pharmaceuticals,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. For information on how to trade TNF Stock refer to our How to Trade TNF Stock guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of TNF Pharmaceuticals,. If investors know TNF will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about TNF Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.48) | Return On Assets (0.32) | Return On Equity (2.98) |
The market value of TNF Pharmaceuticals, is measured differently than its book value, which is the value of TNF that is recorded on the company's balance sheet. Investors also form their own opinion of TNF Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is TNF Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because TNF Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect TNF Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between TNF Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if TNF Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, TNF Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.